Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$67 Mln
P/E Ratio
--
P/B Ratio
1.32
Industry P/E
--
Debt to Equity
0.37
ROE
-0.55 %
ROCE
-41.29 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-181.43 Mln
EBITDA
$-226.93 Mln
Net Profit
$-220.54 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Adagene (ADAG)
| -28.14 | -8.04 | -23.53 | -40.17 | -26.83 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Adagene (ADAG)
| 3.03 | 45.74 | -83.58 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.58 | 10,315.11 | 21.27 | 23.13 | |
| 304.46 | 8,705.27 | 22.77 | 66.44 | |
| 27.63 | 10,589.59 | -- | -28.77 | |
| 108.19 | 10,559.67 | 32.44 | 14.16 |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human... anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China. Address: Building C14, Suzhou, China, 215123 Read more
Co- Founder, Chairman, CEO and President of R&D
Dr. Peter P. Luo Ph.D.
Co- Founder, Chairman, CEO and President of R&D
Dr. Peter P. Luo Ph.D.
Headquarters
Suzhou
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Adagene Inc (ADAG) stood at $ 89 Mln as on 31-Dec-24
The share price of Adagene Inc (ADAG) is $1.43 (NASDAQ) as of 29-Apr-2025 13:12 EDT. Adagene Inc (ADAG) has given a return of -26.83% in the last 3 years.
Adagene Inc (ADAG) has a market capitalisation of $ 67 Mln as on 28-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Adagene Inc (ADAG) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Adagene Inc (ADAG) and enter the required number of quantities and click on buy to purchase the shares of Adagene Inc (ADAG).
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China. Address: Building C14, Suzhou, China, 215123
The CEO & director of Dr. Peter P. Luo Ph.D.. is Adagene Inc (ADAG), and CFO & Sr. VP is Dr. Peter P. Luo Ph.D..
There is no promoter pledging in Adagene Inc (ADAG).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Adagene Inc. (ADAG) | Ratios |
|---|---|
|
Return on equity(%)
|
-55.21
|
|
Operating margin(%)
|
-31578.03
|
|
Net Margin(%)
|
-32386.45
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Adagene Inc (ADAG) was $0 Mln.
